Phase Ⅱ study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas .Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa . Ann Oncol,2010,21:1135-1137 .IDH1 and ID ......